8,918 Shares in Guardant Health, Inc. $GH Bought by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 8,918 shares of the company's stock, valued at approximately $1,338,000.

A number of other hedge funds have also bought and sold shares of GH. Alyeska Investment Group L.P. purchased a new position in shares of Guardant Health during the third quarter valued at approximately $114,421,000. Price T Rowe Associates Inc. MD raised its stake in shares of Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company's stock valued at $575,670,000 after acquiring an additional 1,414,441 shares in the last quarter. Norges Bank purchased a new stake in shares of Guardant Health in the fourth quarter valued at approximately $128,499,000. Summit Partners Public Asset Management LLC grew its stake in Guardant Health by 674.5% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company's stock worth $87,019,000 after purchasing an additional 741,958 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Guardant Health by 89.6% in the first quarter. The Manufacturers Life Insurance Company now owns 1,205,701 shares of the company's stock valued at $111,371,000 after acquiring an additional 569,766 shares in the last quarter. Institutional investors own 92.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. TD Cowen lifted their price objective on shares of Guardant Health from $200.00 to $210.00 and gave the company a "buy" rating in a report on Friday, July 31st. Evercore restated an "outperform" rating and set a $200.00 price target on shares of Guardant Health in a research note on Monday, July 6th. Piper Sandler upped their target price on Guardant Health from $135.00 to $193.00 and gave the company an "overweight" rating in a research report on Tuesday, August 4th. Mizuho raised their target price on Guardant Health from $175.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Finally, Citigroup lifted their price target on Guardant Health from $150.00 to $215.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Guardant Health has a consensus rating of "Moderate Buy" and an average price target of $183.78.

Insider Buying and Selling at Guardant Health

In other news, insider Chris Freeman sold 63,605 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $169.58, for a total value of $10,786,135.90. Following the transaction, the insider owned 65,374 shares in the company, valued at $11,086,122.92. This trade represents a 49.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Amirali Talasaz sold 143,028 shares of the firm's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the completion of the transaction, the chief executive officer directly owned 1,881,336 shares in the company, valued at $285,097,657.44. This trade represents a 7.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 521,818 shares of company stock valued at $77,539,233. 5.60% of the stock is owned by insiders.

Guardant Health Price Performance

NASDAQ:GH opened at $170.69 on Monday. Guardant Health, Inc. has a 52 week low of $53.40 and a 52 week high of $176.58. The stock's 50-day moving average price is $153.91 and its 200-day moving average price is $118.72. The stock has a market capitalization of $22.91 billion, a PE ratio of -48.91 and a beta of 1.60.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to analysts' expectations of $314.23 million. During the same quarter last year, the firm earned ($0.44) earnings per share. The firm's quarterly revenue was up 44.3% compared to the same quarter last year. Sell-side analysts expect that Guardant Health, Inc. will post -2.98 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source